Health-related quality of life and symptoms in patients with IPF treated with nintedanib: Analyses of patient-reported outcomes from the INPULSIS® trials

Respiratory Research

Volumn 21, Issue 1, 2020, Pages

  Kreuter, Michael ^a,b   Wuyts, Wim A ^c   Wijsenbeek, Marlies ^d   Bajwah, Sabrina ^e   Maher, Toby M ^f,g   Stowasser, Susanne ^h   Male, Natalia ^h   Stansen, Wibke ^h   Schoof, Nils ^h   Orsatti, Leticia ^h   Swigris, Jeffrey ⁱ  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b German Center for Lung Research   (Germany)

^c UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^d ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^e KING'S COLLEGE LONDON   (United Kingdom)

^f NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^g ROYAL BROMPTON HOSPITAL   (United Kingdom)

^h BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

ⁱ UNIVERSITY OF COLORADO   (United States)

Author keywords

CASA Q; EQ 5D VAS; SGRQ; UCSD SOBQ

Indexed keywords

CARBON MONOXIDE; NINTEDANIB; PLACEBO; INDOLE DERIVATIVE; PROTEIN KINASE INHIBITOR;

AGED; ARTICLE; CLINICAL FEATURE; COHORT ANALYSIS; CONTROLLED STUDY; DETERIORATION; DISEASE CLASSIFICATION; DISEASE EXACERBATION; DRUG EFFECT; FEMALE; FIBROSING ALVEOLITIS; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HUMAN; LUNG CAPACITY; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PATIENT-REPORTED OUTCOME; POST HOC ANALYSIS; PREDICTION; QUALITY OF LIFE; ST. GEORGE RESPIRATORY QUESTIONNAIRE; SYMPTOM; CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; MIDDLE AGED; PHASE 3 CLINICAL TRIAL; PHYSIOLOGY; PSYCHOLOGY; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; VITAL CAPACITY;

AGED; DOUBLE-BLIND METHOD; FEMALE; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; INDOLES; MALE; MIDDLE AGED; PATIENT REPORTED OUTCOME MEASURES; PROTEIN KINASE INHIBITORS; QUALITY OF LIFE; TREATMENT OUTCOME; VITAL CAPACITY;

EID: 85078709809     PISSN: 14659921     EISSN: 1465993X     Source Type: Journal    
DOI: 10.1186/s12931-020-1298-1     Document Type: Article

References (27)

1. Richeldi L, Collard HR, Jones MG. Idiopathic pulmonary fibrosis. Lancet. 2017;389:1941-52.
2. Olson AL, Swigris JJ, Lezotte DC, Norris JM, Wilson CG, Brown KK. Mortality from pulmonary fibrosis increased in the United States from 1992 to 2003. Am J Respir Crit Care Med. 2007;176:277-84.
3. American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). Am J Respir Crit Care Med. 2000;161:646-64.
4. Kreuter M, Swigris J, Pittrow D, Geier S, Klotsche J, Prasse A, et al. Health related quality of life in patients with idiopathic pulmonary fibrosis in clinical practice: insights-IPF registry. Respir Res. 2017;18:139.
5. Kreuter M, Swigris J, Pittrow D, Geier S, Klotsche J, Prasse A, et al. The clinical course of idiopathic pulmonary fibrosis and its association to quality of life over time: longitudinal data from the INSIGHTS-IPF registry. Respir Res. 2019;20:59.
6. Moor CC, Heukels P, Kool M, Wijsenbeek MS. Integrating patient perspectives into personalized medicine in idiopathic pulmonary fibrosis. Front Med (Lausanne). 2017;4:226.
7. Glaspole IN, Chapman SA, Cooper WA, Ellis SJ, Goh NS, Hopkins PM, et al. Health-related quality of life in idiopathic pulmonary fibrosis: data from the Australian IPF registry. Respirology. 2017;22:950-6.
8. Rajala K, Lehto JT, Sutinen E, Kautiainen H, Myllarniemi M, Saarto T. Marked deterioration in the quality of life of patients with idiopathic pulmonary fibrosis during the last two years of life. BMC Pulm Med. 2018;18:172.
9. Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014;370:2071-82.
10. Swigris JJ, Esser D, Conoscenti CS, Brown KK. The psychometric properties of the St George's respiratory questionnaire (SGRQ) in patients with idiopathic pulmonary fibrosis: A literature review. Health Qual Life Outcomes. 2014;12:124.
11. Swigris JJ, Esser D, Wilson H, Conoscenti CS, Schmidt H, Stansen W, et al. Psychometric properties of the St George's respiratory questionnaire in patients with idiopathic pulmonary fibrosis. Eur Respir J. 2017;49(1). https://doi.org/10.1183/13993003.01788-2016.
12. Jones PW, Quirk FH, Baveystock CM. The St George's Respiratory Questionnaire. Respir Med. 1991;85(Suppl B):25-31 discussion 3-7.
13. Swigris JJ, Han M, Vij R, Noth I, Eisenstein EL, Anstrom KJ, et al. The UCSD shortness of breath questionnaire has longitudinal construct validity in idiopathic pulmonary fibrosis. Respir Med. 2012;106:1447-55.
14. Monz BU, Sachs P, McDonald J, Crawford B, Nivens MC, Tetzlaff K. Responsiveness of the cough and sputum assessment questionnaire in exacerbations of COPD and chronic bronchitis. Respir Med. 2010;104:534-41.
15. Gries KS, Esser D, Wiklund I. Content validity of CASA-Q cough domains and UCSD-SOBQ for use in patients with idiopathic pulmonary fibrosis. Glob J Health Sci. 2013;5:131-41.
16. Szentes BL, Kreuter M, Bahmer T, Birring SS, Claussen M, Waelscher J, et al. Quality of life assessment in interstitial lung diseases: A comparison of the disease-specific K-BILD with the generic EQ-5D-5L. Respir Res. 2018;19:101.
17. du Bois RM, Weycker D, Albera C, Bradford WZ, Costabel U, Kartashov A, et al. Forced vital capacity in patients with idiopathic pulmonary fibrosis: Test properties and minimal clinically important difference. Am J Respir Crit Care Med. 2011;184:1382-9.
18. Richeldi L, Ryerson CJ, Lee JS, Wolters PJ, Koth LL, Ley B, et al. Relative versus absolute change in forced vital capacity in idiopathic pulmonary fibrosis. Thorax. 2012;67:407-11.
19. Lee SH, Park JS, Kim SY, Kim DS, Kim YW, Chung MP, et al. Comparison of CPI and GAP models in patients with idiopathic pulmonary fibrosis: A nationwide cohort study. Sci Rep. 2018;8:4784.
20. Collard HR, Yow E, Richeldi L, Anstrom KJ, Glazer C, investigators IP. Suspected acute exacerbation of idiopathic pulmonary fibrosis as an outcome measure in clinical trials. Respir Res. 2013;14:73.
21. Koyama K, Sakamoto S, Isshiki T, Shimizu H, Kurosaki A, Homma S. The activities of daily living after an acute exacerbation of idiopathic pulmonary fibrosis. Intern Med. 2017;56:2837-43.
22. King TE Jr, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014;370:2083-92.
23. Noble PW, Albera C, Bradford WZ, Costabel U, Glassberg MK, Kardatzke D, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): Two randomised trials. Lancet. 2011;377:1760-9.
24. Glassberg MK, Wijsenbeek MS, Gilberg F, Petzinger U, Kirchgaessler KU, Albera C. Effect of pirfenidone on breathlessness in patients with idiopathic pulmonary fibrosis. Eur Respir J. 2019;54(3). https://doi.org/10.1183/13993003.00399-2019.
25. Nathan SD, Costabel U, Albera C, Behr J, Wuyts WA, Kirchgaessler KU, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis and more advanced lung function impairment. Respir Med. 2019;153:44-51.
26. van Manen MJG, Birring SS, Vancheri C, Vindigni V, Renzoni E, Russell AM, et al. Effect of pirfenidone on cough in patients with idiopathic pulmonary fibrosis. Eur Respir J. 2017;50(4). https://doi.org/10.1183/13993003.01157-2017.
27. Visca D, Mori L, Tsipouri V, Fleming S, Firouzi A, Bonini M, et al. Effect of ambulatory oxygen on quality of life for patients with fibrotic lung disease (AmbOx): A prospective, open-label, mixed-method, crossover randomised controlled trial. Lancet Respir Med. 2018;6:759-70.